Appl. No. 09/673,139 Amendment dated July 27, 2004 Reply to Office Action of January 27, 2004 Attorney Ref. No.: 068800-0277860

II. REMARKS

Preliminary Remarks:

Claims 1, 7, 9, 15, 18, and 23 are amended.

Claims 1 and 15 are amended to specify the feature that the ions are incorporated at a level whereby bone ongrowth onto the implant is enhanced as compared with unmodified bioactive material. Support for this amendment may be found on page 3, seven lines from the bottom.

Claim 1 is further amended to specify that the ions are incorporated into the bioactive material by ion beam implantation, support for which is found in the specification at the top of page 3, and in the originally filed claim.

Claims 7 and 9 are amended by replacing the word "AND" in upper case with the lower case form. The upper case form of "and" was introduced into claims 7 and 9 by a clerical error in the amendment filed October 30, 2002.

Claim 18 is amended to depend on independent claim 15 rather than on canceled claim 17. The subject matter of original claim 17 was incorporated into claim 15 by the amendment filed October 24, 2003.

Claim 23 is amended by inserting the words "groups of the" before "periodic table." The amendment restores the claim to its original form. The added words were inadvertently dropped from their place before the words "periodic table" in original claim 23 as it was printed in the list of pending claims in the amendment filed October 24, 2003.

The foregoing amendments do not add new matter.

Patentability Remarks:

Objections

Claims 18 and 19 were objected to because of their dependence on canceled claim 17. Claim 18 has been amended to depend on claim 15. Accordingly, withdrawal of the objection to claims 18 and 19 stated in the official action is respectfully requested.

Appl. No. 09/673,139
Amendment dated July 27, 2004
Reply to Office Action of January 27, 2004
Attorney Ref. No.: 068800-0277860

35 U.S.C. §103(a)

Claims 1, 2, 4-13, and 26 were rejected under 35 U.S.C. §103(a) as being obvious in view of U.S. Patent No. 5,188,670 of Constantz et al. (hereinafter "Constantz").

Claims 1, 2, 4-13, 15, 16, 18-24, and 26 were rejected under 35 U.S.C. §103(a) as being obvious in view of U.S. Patent No. 5,817,326 of Nastasi et al. (hereinafter "Nastasi").

The applicants respectfully traverse both of these grounds for rejection.

A. Description of the Present Invention

The provision of bone implants with a coating of a bioactive material such as hydroxyapatite is well known. *In situ*, the coating of bioactive material enables bone ongrowth onto the implant. In the absence of such coating bone does not become physically and chemically bonded to the implant (see the Background section of the present specification).

The present invention is directed to improving the bone ongrowth properties of bone implants. In other words, the invention is concerned with improving the bioactivity of the surface of the implant. The invention achieves this improvement by incorporating ions from the selected groups of the periodic table set out in claim 1. The ions are incorporated into or onto the surface of the bone implant by ion beam implantation up to a maximum depth of 200 nm. This feature makes it clear that the ions are incorporated only at the surface of the coated implant i.e. only at the surface of the bioactive material. This alters the surface chemistry of the surface material to the extent that there is an increase in its bioactivity. The surface structure and mechanical properties are not substantially affected. This is important because the strength and longevity of the implant do not suffer.

In order to achieve the enhanced bioactivity of the surface material the ions are incorporated into the surface at a relatively dilute level. This feature is reflected in a proposed amendment to claim 1 which is attached. Feature (c) of claim 1 now indicates that the ions are incorporated at a level whereby bone ongrowth onto the implant is enhanced as compared with unmodified bioactive material. The inventors believe that the ions (which may form atoms in situ) locate in the interstices of the bioactive material coating. Thus, according to the invention, there is no coating of the bioactive surface by the implanted ions. The enhanced bioactivity achieved by the ion implantation of the present invention is

Appl. No. 09/673,139 Amendment dated July 27, 2004 Reply to Office Action of January 27, 2004 Attorney Ref. No.: 068800-0277860

therefore achieved by interstitial incorporation of atoms/ions just at the surface of the bioactive coating. The effect of this incorporation is to increase bone ongrowth onto the bioactive material and to increase mechanical bonding of the bioactive coating to bone. This result is surprising and was not predicted by the prior art.

B. Comparison of the claimed invention to the prior art

The official action cited the two prior art references of Constantz and Nastasi against the present claims. Neither Constantz nor Nastasi described or suggested the present invention. Both of these documents are concerned with the production of hydroxyapatite coatings in several layers. Each layer of hydroxyapatite is bound to the next and the hydroxyapatite coating forms a bond with the underlying metal of the implant. Thus, both Constantz and Nastasi are concerned with treatments of the metal or hydroxyapatite so as to improve the strength of the bond between layers. Neither of these documents is concerned with an enhancement of bioactivity of the hydroxyapatite coating of the coated implant.

Nastasi et al.

Nastasi is concerned with the application to a titanium surface of successive layers of hydroxyapatite to strengthen the adhesion of the hydroxyapatite coatings to the titanium alloy (col 3, lines 2 and 3). Col 5, line 5 indicates that subsequent layers of hydroxyapatite are added to provide a gentle density gradient. This passage indicates that the final layered prosthesis would provide greater strength than those presently available. The total coating thickness is indicated to be between 50 and 200 μ m (50,000 to 200,000 nm).

The entire purpose of Nastasi is to alter the mechanical strength of the prosthesis and not to alter the bioactivity of the surface of the hydroxyapatite coating. This is made clear in claim 1 of Nastasi where it is indicated that ions from the ion implantation step are used to densify the hardened hydroxyapatite layer and penetrate the densified hydroxyapatite layer to travel into the titanium alloy prosthesis. It follows that this ion implantation treatment would enable the ions to penetrate the total coating thickness of up to 200,000 nm – three orders of magnitude larger than the 200 nm required by the present invention.

This contrasts completely with the present invention where ion implantation occurs only at the very surface of the hydroxyapatite coating so that the mechanical strength of the

implant is not affected. There is no disclosure or suggestion in Nastasi that the ions should be incorporated only to a maximum depth of 200 nm and there is no disclosure or suggestion that the ions should be incorporated at a level whereby bone ongrowth onto the implant is enhanced. This is because Nastasi is concerned entirely with the mechanical structure of the implant and not with the bioactivity of the surface of the bioactive hydroxyapatite layer. If it is the intention of Nastasi to improve the bonding between metal and hydroxyapatite coating, this would have absolutely no bearing on the bioactivity of the surface of the hydroxyapatite coating in Nastasi. Indeed, given that Nastasi has as its sole purpose the alteration of the mechanical strength and structure of titanium alloy prostheses, it could not have been obvious to the skilled reader to have applied an ion beam implantation method to a very narrow surface region of the hydroxyapatite coating when Nastasi expressly teaches a treatment which penetrates multiple layers of coating. Nastasi therefore teaches away from the present invention, and the invention would not have been obvious to a person of ordinary skill in the art in view of Nastasi.

Constantz et al.

Constantz is similarly concerned with multiple layers of hydroxyapatite (col. 3, lines 22 et seq). Lines 49 to 51 of column 3 indicate that the total thickness of the second and succeeding layers would generally be in the range of 5 μm to 20 μm (5,000 nm to 20,000 nm). Constantz does not disclose ion beam implantation and the methods used in Constantz would not achieve the interstitial incorporation of atoms or ions in the first 200 nm at the surface of a bioactive hydroxyapatite coating required by the present invention. Instead, Constantz is concerned only with wet chemistry and does not describe ion beam treatment at all. Col 3, lines 52 et seq indicate the various methods by which the chemistry of Constantz is carried Constantz actually teaches modification of the hydroxyapatite for the purpose of influencing the in vivo dissolution behaviour of the coating itself (col 2, lines 53 to 55). The chemical structure of the hydroxyapatite is actually altered by the use of the ions applied in solution. According to col. 2, lines 52 and 53, phosphate and hydroxide anions of the hydroxyapatite and up to 50% of the calcium cations will be substituted with other ions. This represents a potentially significant proportion of the hydroxyapatite whose chemical constitution would be affected in this way. The result of Constantz would be to provide a chemically modified coating potentially to a depth of the hydroxyapatite significantly in

Appl. No. 09/673,139 Amendment dated July 27, 2004 Reply to Office Action of January 27, 2004 Attorney Ref. No.: 068800-0277860

excess of the depth specified in the present invention. The purpose of this coating is to affect the resorbability of the coating itself and not to enhance the bioactivity of the surface of the hydroxyapatite coating. We submit that it would not have been obvious to the skilled addressee to have turned to ion beam implantation as a means to achieve the purpose of Constantz. Equally, to address the problem of bioactivity, there is no motivation from Constantz to turn to ion beam implantation. Even if ion beam implantation had been considered, Constantz teaches chemical modification by providing a coating to affect hydroxyapatite resorbability. There is no disclosure or suggestion of increased bone ongrowth onto the coating or increased mechanical bonding of the hydroxyapatite coating to bone. Nothing in Constantz provides a teaching that ions should be incorporated at a sufficient level whereby bone ongrowth onto the implant is enhanced as compared with unmodified bioactive material.

For the reasons set forth above, neither Nastasi nor Constanz would have provided suggestion or motivation to one of ordinary skill in the art to practice the claimed invention. Accordingly, withdrawal of the rejections of claims under 35 U.S.C. §103(a) as being obvious in view of Nastasi and Constantz is respectfully requested.

Conclusion

All rejections having been addressed, it is respectfully submitted that the present application is in condition for allowance and a Notice to that effect is earnestly solicited. If any points remain in issue, which the examiner feels may be best resolved through a personal or telephone interview, he is kindly requested to contact the undersigned attorney at the telephone number listed below.

Respectfully submitted,

PILLSBURY WINTHROP, LLP

Thomas A. Cawley, Jr., Ph.D.

Reg. No.: 40944

Tel. No.: (703) 905-2144 Fax No.: (703) 905-2500

PILLSBURY WINTHROP LLP P.O. Box 10500 McLean, VA 22102